A Comprehensive Review of Management of Colorectal Liver Mets in the Current Era

Overview

Journal Cancer Med J

Date 2022 Feb 18

PMID 35178538

Authors

Hassan Aziz

Zubair Ahmed

Yi Lee

Gavin Drumm

Muhammad Wasif Saif

Affiliations

Soon will be listed here.

Abstract

Colorectal carcinoma is the third most common cancer in the US. The liver tends to be the most common site of metastasis. This review provides an in-depth analysis of non-transplant options available in the management of colorectal liver mets.

Citing Articles

Long-Term Outcome After Resection of Hepatic and Pulmonary Metastases in Multivisceral Colorectal Cancer.

Berlin C, Andrieux G, Menzel M, Stoger G, Gengenbach A, Schafer L Cancers (Basel). 2024; 16(22).

PMID: 39594697 PMC: 11592306. DOI: 10.3390/cancers16223741.

Characterization of metastasis-specific macrophages in colorectal cancer for prognosis prediction and immunometabolic remodeling.

Hua Y, Ma X, Zhao X, Wei X, Mu X, Zhang X Sci Rep. 2024; 14(1):26361.

PMID: 39487182 PMC: 11530676. DOI: 10.1038/s41598-024-77248-2.

Liver transplantation for non-resectable colorectal liver metastases.

Aziz H, Sharif S, Gribovskaja-Rupp I, Hemming A Hepatobiliary Surg Nutr. 2023; 12(4):595-597.

PMID: 37601003 PMC: 10432297. DOI: 10.21037/hbsn-23-270.

References

Adams R, Aloia T, Loyer E, Pawlik T, Taouli B, Vauthey J . Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15(2):91-103. PMC: 3719914. DOI: 10.1111/j.1477-2574.2012.00557.x. View

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

Allen P, Nissan A, Picon A, Kemeny N, Dudrick P, Ben-Porat L . Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005; 201(1):57-65. DOI: 10.1016/j.jamcollsurg.2005.03.019. View

Tang W, Ren L, Liu T, Ye Q, Wei Y, He G . Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial. J Clin Oncol. 2020; 38(27):3175-3184. DOI: 10.1200/JCO.20.00174. View

Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D . A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008; 27(5):672-80. DOI: 10.1200/JCO.2008.19.8135. View

Gallagher D, Kemeny N . Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010; 78(3-4):237-48. DOI: 10.1159/000315730. View

Mitchell D, Puckett Y, Nguyen Q . Literature Review of Current Management of Colorectal Liver Metastasis. Cureus. 2019; 11(1):e3940. PMC: 6433446. DOI: 10.7759/cureus.3940. View

Benoist S, Nordlinger B . The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009; 16(9):2385-90. DOI: 10.1245/s10434-009-0492-7. View

Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-17. DOI: 10.1056/NEJMoa0805019. View

10.

Pak L, Kemeny N, Capanu M, Chou J, Boucher T, Cercek A . Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol. 2017; 117(4):634-643. PMC: 5878699. DOI: 10.1002/jso.24898. View

11.

Vauthey J, Pawlik T, Ribero D, Wu T, Zorzi D, Hoff P . Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24(13):2065-72. DOI: 10.1200/JCO.2005.05.3074. View

12.

Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A . A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992; 69(2):327-34. DOI: 10.1002/1097-0142(19920115)69:2<327::aid-cncr2820690209>3.0.co;2-u. View

13.

ENSMINGER W, Gyves J . Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983; 10(2):176-82. View

14.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

15.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo.... J Clin Oncol. 2007; 25(13):1670-6. DOI: 10.1200/JCO.2006.09.0928. View

16.

Maher B, Ryan E, Little M, Boardman P, Stedman B . The management of colorectal liver metastases. Clin Radiol. 2017; 72(8):617-625. DOI: 10.1016/j.crad.2017.05.016. View

17.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

18.

Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306(6880):752-5. PMC: 1677246. DOI: 10.1136/bmj.306.6880.752. View

19.

Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2003; 22(1):23-30. DOI: 10.1200/JCO.2004.09.046. View

20.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View